medigraphic.com
Organo Oficial de la Sociedad Mexicana de Urología

2007, Number 2

<< Back Next >>

Rev Mex Urol 2007; 67 (2)

Expresión del gen DD3PCA3 en cáncer de próstata e hiperplasia prostática benigna. Estudio en el Hospital Central Militar de México

Floriano-Sánchez E, Amador-Ortega J, Castro-Marín M, Torres-Salazar JJ, Ricardos-Espinoza AA, Tavera-Ramirez G, López-Silvestre JC, Aboytes-Velásquez EA

Language: Spanish
References: 38
Page: 93-101
PDF size: 314.05 Kb.


ABSTRACT

In 70% of the cases, the prostate cancer is detected in advanced stadiums, for that the gene DD3 PCA3 is an interesting marker candidate for diagnose and predict, since it’s one of those but specific for the prostate cancer.
Objective. To determine and to analyze the expression of the gene DD3PCA3, in tissue with prostate cancer and BPH.
Methods. In this study we carry out the quantification of the mRNA of the gene DD3PCA3 developing the methodology to determine the expression using the transcription reverse-PCR time-real (Rotor-Gene 3000).
Results. The expression of the DD3PCA3 was determined in prostate cancer and it was compared with benign hyperplasia, being expressed 30.4 times (p‹ 0.0001) in the neoplasm; the expression average for the neoplasm and hyperplasia was respectively of 1745 and 57.4.
Conclusions. In this study we found that there is expression of the gene significantly bigger DD3PCA3 in the neoplasm compared with the hyperplasia; for that this gene can be used as a marker early tumoral, being carried out in biopsies of patient with suspicion of prostate cancer.


REFERENCES

  1. Hall SE, Holman C, Wisniewski ZS, Semmens J. Prostate cancer: socio-economic, geographical and private-health insurance effects on care and survival. BJU Int. 2005;95(1):51-8.

  2. Haas GP, Sakr WA. Epidemiology of prostate cancer. CA Cancer J Clin. 1997;47(5):273-87.

  3. Jemal A, Murray T, Ward E, et al. Cancer statistics 2005. CA Cancer J Clin. 2005;55(1):10-30.

  4. Ahmed MM, Lee CT, Oesterling JE. Current trend in the epidemiology of prostatic disease: benign hyperplasia and adenocarcinoma. En: RK Naz (ed), Prostate: Basic and Clinical Aspects, pp. 3-25. Boca Raton, Florid: CRC Press, 1997.

  5. Mistry K, Cable G. Meta-analysis of Prostate-Specific Antigen and Digital Rectal Examination as Screening Tests for Prostate Carcinoma. J Am Board Farm Pract. 2003;16(2):95-101.

  6. Lepor H, Owens RS, Rogenes V, Kuhn E. Detection of prostate cancer in males with prostatism. Prostate. 1994;25:132.

  7. Babaian RJ, Johnston DA, Naccarato W, et al. The incidence of prostate cancer in a screening population with a serum prostate specific antigen between 2.5 and 4.0 ng/ml: relationship to biopsy strategy. J Urol. 2001;165(3):757-60.

  8. Catalona WJ, Smith DS, Ornstein DK. Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/ml and benign prostatic examination: enhancement of specificity with free PSA measurements. JAMA. 1997;277:1452-55.

  9. Thompson IM, Pauler DK, Goodman PJ, et al. Prevalence of prostate cancer among men with a prostatespecific antigen level < or 4.0 ng per milliliter. N Engl J Med. 2004;350(2):2239-46.

  10. Kupelian PA, Elshaihk M, Reddy CA, Zippe C, Klein EA. Comparison of the efficacy of local therapies for localized prostate cancer in the PSA era: large single institution experience with radical prostatectomy and external beam radiotherapy. J Clin Oncol. 2002;20(16):3376-85.

  11. Kupelian PA, Potters L, Khuntia D, et al. Radical prostatectomy, external beam radiotherapy <72 Gy, external beam radiotherapy ≥72 Gy, permanent seed implantation, or combined seeds/external beam radiotherapy for stage T1-T2 prostate cancer. Intl J Radiat Oncol Biol Phys. 2004;58:25-33.

  12. Van Iersel MP, Witjes WP, de la Rosette JJ, Oosterhof GO. Prostate specific antigen density: correlation with histological diagnosis of prostate cancer, benign prostatic hyperplasia and prostatitis. Br J Urol. 1995;76:47-53.

  13. Crawford E, DeAntoni E, Ross C. The role of prostatespecific antigen in the chemoprevention of prostate cancer. J Cell Biochem. 1996;25(Suppl):149-155.

  14. Carter HB, Morrell CH, Pearson JD, et al. Estimation of prostatic growth using serial prostate-specific antigen measurements in men with and without prostate disease. Cancer Res. 1992;52:3323-8.

  15. Paul B, Dhir R, Landsittel D, et al. Detection of prostate cancer with a blood-based assay for early prostate cancer antigen. Cancer Res. 2005;65:4097-100.

  16. Bussemakers MJ, van Bokhoven A, Verhaegh GW, et al. DD3: a new prostate-specific gene, highly overexpressed in prostate cancer. Cancer Res. 1999;59(23):5975-9.

  17. Tomlins SA, Rhodes DR, Perner S, et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science. 2005;310:644-8.

  18. Landers KA, Burger MJ, Purdie MD, Scells B, et al. Use of multiple biomarkers for a molecular diagnosis of prostate cancer. Int J Cancer. 2005; 114(6): 950-6.

  19. de Kok JB, Zendman AJ, van de Locht LT, Ruers TJ, van Muijen GN, Mensink E, Swinkels DW. Real-time hTERT quantification: a promising telomerase-associated tumor marker. Lab Investig. 1999;79:911-2.

  20. Xu LL, Stackhouse BG, Florence K, et al. PSGR, a novel prostate-specific gene with homology to a G protein- coupled receptor, is overexpressed in prostate cancer. Cancer Res. 2000;60:6568-72.

  21. Srikantan V, Zou Z, Petrovics G, Xu L, et al. PCGEM1, a prostate-specific gene, is overexpressed in prostate cancer. Proc. Natl Acad Sci USA. 2000;97:12216-21.

  22. Schalken JA, Hessels D, Verhaegh G. New targets for therapy in prostate cancer: differential display code 3 (DD3(PCA3)), a highly prostate cancer-specific gene. Urology. 2003;62(Suppl 1):34-43.

  23. Hessels D, Verhaegh GW, Schalken JA, Witjes A. Applicability of biomarkers in the early diagnosis of prostate cancer. Expert Rev Mol Diagn. 2004;4:513-26.

  24. De Kok JB, Verhaegh GW, Roelofs RW, et al. DD3 (PCA3), a very sensitive and specific marker to detect prostate tumors. Cancer Res. 2002;62(9):2695-8.

  25. Schalken JA, Hessels D, Verhaegh G. New targets for therapy in prostate cancer: differential display code 3 (DD3(PCA3)), a highly prostate cancer-specific gene. Urology. 2003;62(Suppl 1):34-43.

  26. Bostwick DG, Gould VE, Marberger M. Prostate cancer detected by uPM3: radical prostatectomy findings. Modern Pathology. 2006;19:630-3.

  27. Fradet Y, Saad F, Aprikian A, Dessureault J, et al. uPM3, a new molecular urine test for the detection of prostate cancer. Urology. 2004;64(2):311-6.

  28. Gandini O, Luci L, Stigliano A, et al. Is DD3 a new prostate- specific gene? Anticancer Res. 2003;23(1A): 305-8.

  29. Hessels D, Klein Gunnewiek JM, van Oort I, et al. DD3 (PCA3)-based molecular urine analysis for the diagnosis of prostate cancer. Eur Urol. 2003;44(1):8-16.

  30. Gibson UE, Heid CA, Williams PM. A novel method for real time quantitative RT-PCR. Genome Res. 1996;6(10):1095-2001.

  31. Haberhausen G, Pinsl J, Kuhn CC, Markert-Hahn C. Comparative study of different standardization concepts in quantitative competitive reverse transcription-PCR assays. J Clin Microbiol. 1998;36:628-33.

  32. Pfaffl MW, Tichopad A, Prqomet C, Neuvians TP. Determination of stable housekeeping genes, differentially regulated target genes and sample integrity: BestKeeper – Excel-based tool using pair-wise correlations. Biotechnology Lett. 2004;26(6):509-15.

  33. Pfaffl MW, Horgan GW, Dempfle L. Relative expression software tool (REST) for group-wise comparison and statistical analysis of relative expression results in real-time PCR. Nucleic Acids Res. 2002;30(9):e36.

  34. Hessels D, Klein Gunnewiek JM, van Oort I, Karthaus HF, van Leenders GJ, van Balken B, et al. DD3(PCA3)- based molecular urine analysis for the diagnosis of prostate cancer. Eur Urol. 2003;44(1):8-16.

  35. Landers KA, Burger MJ, Tebay MA, Purdie DM, Scells B, Samaratunga H, Lavin MF, Gardiner RA. Use of multiple biomarkers for a molecular diagnosis of prostate cancer. Int J Cancer. 2005;114(6):950-6.

  36. Tasken KA, Angelsen A, Svindland A, Eide T, Berge V, Wahlquist R, Karlsen S. Markers for diagnosis, prediction and prognosis of prostate cancer [abstract]. Tidsskr Nor Laegeforen. 2005;125(23):3279-82.

  37. Fradet Y, Saad F, Aprikian A, Dessureault J, et al. uPM3, a new molecular urine test for the detection of prostate cancer. Urology. 2004;64(2):311-6.

  38. Bostwick DG, Gould VE, Qian J, Susani M, Marberger M. Prostate cancer detected by uPM3: radical prostatectomy findings. Mod Pathol. 2006;19(5):630-3.




2020     |     www.medigraphic.com